版本:
中国

BRIEF-Phase 3 study with filgotinib initiated in crohn's disease

Nov 22 Galapagos Nv

* Phase 3 study with filgotinib initiated in crohn's disease

* Galapagos NV says start of diversity study triggers a $50 million milestone payment from Gilead Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐